MDM2 SNP309 is associated with high grade node positive breast tumours and is in linkage disequilibrium with a novel MDM2 intron 1 polymorphism

BMC Cancer

Volumn 8, Issue , 2008, Pages

  Paulin, Fiona E M ^a,b   O'Neill, Mary ^a,c   McGregor, Gillian ^a,b   Cassidy, Andrew ^a,d   Ashfield, Alison ^a,c   Ali, Clinton W ^a,e   Munro, Alastair J ^a,d   Baker, Lee ^a,c   Purdie, Colin A ^a,e   Lane, David P ^a,f   Thompson, Alastair M ^a,d  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

^b National Translational Cancer Research Network   (United Kingdom)

^c Breast Cancer Research   (United Kingdom)

^d UNIVERSITY OF DUNDEE   (United Kingdom)

^e NHS TAYSIDE   (United Kingdom)

^f Cancer Research   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN RECEPTOR; PROTEIN MDM2; MDM2 PROTEIN, HUMAN; TUMOR MARKER;

ADULT; AGE; ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; BREAST TUMOR; CANCER GRADING; CANCER SUSCEPTIBILITY; CAUCASIAN; CLINICAL FEATURE; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; GENE FREQUENCY; GENE LINKAGE DISEQUILIBRIUM; GENETIC SUSCEPTIBILITY; GENOTYPE; HOMOZYGOSITY; HUMAN; INTRON; MAJOR CLINICAL STUDY; MALE; MENOPAUSE; PENETRANCE; POLYMERASE CHAIN REACTION; PROGNOSIS; SINGLE NUCLEOTIDE POLYMORPHISM; UNITED KINGDOM; CASE CONTROL STUDY; CHEMISTRY; GENETIC PREDISPOSITION; GENETICS; ONSET AGE; PATHOLOGY; REGRESSION ANALYSIS;

AGE OF ONSET; BREAST NEOPLASMS; CASE-CONTROL STUDIES; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; INTRONS; LINKAGE DISEQUILIBRIUM; MALE; MENOPAUSE; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-MDM2; RECEPTORS, ESTROGEN; REGRESSION ANALYSIS; SCOTLAND; TUMOR MARKERS, BIOLOGICAL;

EID: 55349146001     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-8-281     Document Type: Article

References (54)

1. Momand J Zambetti GP Olson DC George D Levine AJ The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation Cell 1992, 69(7):1237-1245. 10.1016/0092-8674(92)90644-R 1535557
2. Vogelstein B Lane D Levine AJ Surfing the p53 network Nature 2000, 408(6810):307-310. 10.1038/35042675 11099028
3. Hupp TR Lane DP Ball KL Strategies for manipulating the p53 pathway in the treatment of human cancer Biochem J 2000, 352(Pt 1):1-17. 1221427 11062053 10.1042/0264-6021:3520001
4. Oliner JD Pietenpol JA Thiagalingam S Gyuris J Kinzler KW Vogelstein B Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53 Nature 1993, 362(6423):857-860. 10.1038/362857a0 8479525
5. Michael D Oren M The p53-Mdm2 module and the ubiquitin system Semin Cancer Biol 2003, 13(1):49-58. 10.1016/S1044-579X(02)00099-8 12507556
6. Zauberman A Flusberg D Haupt Y Barak Y Oren M A functional p53-responsive intronic promoter is contained within the human mdm2 gene Nucleic Acids Res 1995, 23(14):2584-2592. 307078 7651818 10.1093/nar/ 23.14.2584
7. Cordon-Cardo C Latres E Drobnjak M Oliva MR Pollack D Woodruff JM Marechal V Chen J Brennan MF Levine AJ Molecular abnormalities of mdm2 and p53 genes in adult soft tissue sarcomas Cancer Res 1994, 54(3):794-799. 8306343
8. Watanabe T Hotta T Ichikawa A Kinoshita T Nagai H Uchida T Murate T Saito H The MDM2 oncogene overexpression in chronic lymphocytic leukemia and low-grade lymphoma of B-cell origin Blood 1994, 84(9):3158-3165. 7949188
9. Quesnel B Preudhomme C Fournier J Fenaux P Peyrat JP MDM2 gene amplification in human breast cancer Eur J Cancer 1994, 30A(7):982-984. 10.1016/0959-8049(94)90128-7 7946596
10. Ziyaie D Hupp TR Thompson AM P53 and breast cancer Breast 2000, 9(5):239-246. 10.1054/brst.2000.0199 14732173
11. Bond GL Hu W Bond EE Robins H Lutzker SG Arva NC Bargonetti J Bartel F Taubert H Wuerl P A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans Cell 2004, 119(5):591-602. 10.1016/ j.cell.2004.11.022 15550242
12. Harris SL Gil G Robins H Hu W Hirshfield K Bond E Bond G Levine AJ Detection of functional single-nucleotide polymorphisms that affect apoptosis Proc Natl Acad Sci USA 2005 102 45 16297 16302 1283473 16260726 10.1073/pnas.0508390102
13. Toyama T Zhang Z Nishio M Hamaguchi M Kondo N Iwase H Iwata H Takahashi S Yamashita H Fujii Y Association of TP53 codon 72 polymorphism and the outcome of adjuvant therapy in breast cancer patients Breast Cancer Res 2007, 9(3):R34. 1929098 17537232 10.1186/bcr1682
14. Park SH Choi JE Kim EJ Jang JS Han HS Lee WK Kang YM Park JY MDM2 309T>G polymorphism and risk of lung cancer in a Korean population Lung Cancer 2006, 54(1):19-24. 10.1016/j.lungcan.2006.06.008 16876289
15. Millikan RC Heard K Winkel S Hill EJ Heard K Massa B Mayes L Williams P Holston R Conway K No association between the MDM2 -309 T/G promoter polymorphism and breast cancer in African-Americans or Whites Cancer Epidemiol Biomarkers Prev 2006, 15(1):175-177. 10.1158/ 1055-9965.EPI-05-0692 16434608
16. Wilkening S Bermejo JL Hemminki K MDM2 SNP309 and Cancer Risk: A Combined Analysis Carcinogenesis 2007, 289(11):2262-2267. 10.1093/carcin/ bgm191 17827408
17. NHSBSP NHS Cancer Screening Programmes and The Royal College of Pathologists Pathology Reporting of Breast Disease; 2005. 58
18. Galea MH Blamey RW Elston CE Ellis IO The Nottingham Prognostic Index in primary breast cancer Breast Cancer Res Treat 1992, 22(3):207-219. 10.1007/BF01840834 1391987
19. Detre S Saclani Jotti G Dowsett M A "quickscore" method for immunohistochemical semiquantitation: Validation for oestrogen receptor in breast carcinomas J Clin Pathol 1995, 48(9):876-878. 502883 7490328 10.1136/jcp.48.9.876
20. Ellis IO Bartlett J Dowsett M Humphreys S Jasani B Miller K Pinder SE Rhodes A Walker R Best Practice No 176: Updated recommendations for HER2 testing in the UK J Clin Pathol 2004, 57(3):233-237. 1770242 14990588 10.1136/jcp.2003.007724
21. Barrett JC Fry B Maller J Daly MJ Haploview: Analysis and visualization of LD and haplotype maps Bioinformatics 2005, 21(2):263-265. 10.1093/ bioinformatics/bth457 15297300
22. Campbell IG Eccles DM Choong DY No association of the MDM2 SNP309 polymorphism with risk of breast or ovarian cancer Cancer Lett; 2005.
23. Bond GL Hirshfield KM Kirchhoff T Alexe G Bond EE Robins H Bartel F Taubert H Wuerl P Hait W MDM2 SNP309 accelerates tumor formation in a gender-specific and hormone-dependent manner Cancer Res 2006, 66(10):5104-5110. 10.1158/0008-5472.CAN-06-0180 16707433
24. Kinyamu HK Archer TK Estrogen receptor-dependent proteasomal degradation of the glucocorticoid receptor is coupled to an increase in mdm2 protein expression Mol Cell Biol 2003, 23(16):5867-5881. 166332 12897156 10.1128/ MCB.23.16.5867-5881.2003
25. el-Deiry WS Tokino T Velculescu VE Levy DB Parsons R Trent JM Lin D Mercer WE Kinzler KW Vogelstein B WAF1, a potential mediator of p53 tumor suppression Cell 1993, 75(4):817-825. 10.1016/0092-8674(93)90500-P 8242752
26. Boersma BJ Howe TM Goodman JE Yfantis HG Lee DH Chanock SJ Ambs S Association of breast cancer outcome with status of p53 and MDM2 SNP309 J Natl Cancer Inst 2006, 98(13):911-919. 16818855
27. Campbell IG Eccles DM Choong DY No association of the MDM2 SNP309 polymorphism with risk of breast or ovarian cancer Cancer Lett 2006, 2409(2):195-197. 10.1016/j.canlet.2005.09.003 16239061
28. Copson ER White HE Blaydes JP Robinson DO Johnson PW Eccles DM Influence of the MDM2 single nucleotide polymorphism SNP309 on tumour development in BRCA1 mutation carriers BMC Cancer 2006, 6:80. 1483833 16563154 10.1186/1471-2407-6-80
29. Cox DG Deer D Guo Q Tworoger SS Hankinson SE Hunter DJ De Vivo I The p53 Arg72Pro and MDM2 -309 polymorphisms and risk of breast cancer in the nurses' health studies Cancer Causes Control 2007, 18(6):621-625. 10.1007/s10552-007-9004-x 17387621
30. Ma H Hu Z Zhai X Wang S Wang X Qin J Jin G Liu J Wang X Wei Q Polymorphisms in the MDM2 promoter and risk of breast cancer: A case-control analysis in a Chinese population Cancer Lett 2006, 240(2):261-267. 10.1016/j.canlet.2005.09.019 16288830
31. Petenkaya A Bozkurt B Akilli-Ozturk O Kaya HS Gur-Dedeoglu B Yulug IG Lack of association between the MDM2-SNP309 polymorphism and breast cancer risk Anticancer Res 2006, 26(6C):4975-4977. 17214373
32. Singh V Rastogi N Mathur N Singh K Singh MP Association of Polymorphism in MDM-2 and p53 Genes with Breast Cancer Risk in Indian Women Ann Epidemiol; 2007. 17719241
33. Wasielewski M Nagel JH Brekelmans C Klijn JG Ouweland van den A Meijers-Heijboer H Schutte M MDM2 SNP309 accelerates familial breast carcinogenesis independently of estrogen signaling Breast Cancer Res Treat 2007, 104(2):153-157. 10.1007/s10549-006-9407-5 17080308
34. Wilkening S Bermejo JL Burwinkel B Klaes R Bartram CR Meindl A Bugert P Schmutzler RK Wappenschmidt B Untch M The single nucleotide polymorphism IVS1+309 in mouse double minute 2 does not affect risk of familial breast cancer Cancer Res 2006, 66(2):646-648. 10.1158/ 0008-5472.CAN-05-3168 16423991
35. Alazzouzi H Suriano G Guerra A Plaja A Espin E Armengol M Alhopuro P Velho S Shinomura Y Gonzalez-Aguilera JJ Tumour selection advantage of non-dominant negative P53 mutations in homozygotic MDM2-SNP309 colorectal cancer cells J Med Genet 2007, 44(1):75-80. 10.1136/ jmg.2006.042572 16825434
36. Alhopuro P Ylisaukko-Oja SK Koskinen WJ Bono P Arola J Jarvinen HJ Mecklin JP Atula T Kontio R Makitie AA The MDM2 promoter polymorphism SNP309T→G and the risk of uterine leiomyosarcoma, colorectal cancer, and squamous cell carcinoma of the head and neck J Med Genet 2005, 42(9):694-698. 1736129 16141004 10.1136/jmg.2005.031260
37. Sotamaa K Liyanarachchi S Mecklin JP Jarvinen H Aaltonen LA Peltomaki P de la Chapelle A p53 codon 72 and MDM2 SNP309 polymorphisms and age of colorectal cancer onset in Lynch syndrome Clin Cancer Res 2005, 11(19 Pt1): 6840-6844. 10.1158/1078-0432.CCR-05-1139 16203772
38. Pine SR Mechanic LE Bowman ED Welsh JA Chanock SC Shields PG Harris CC MDM2 SNP309 and SNP354 are not associated with lung cancer risk Cancer Epidemiol Biomarkers Prev 2006, 15(8):1559-1561. 10.1158/ 1055-9965.EPI-06-0217 16896050
39. Zhou G Zhai Y Cui Y Zhang X Dong X Yang H He Y Yao K Zhang H Zhi L MDM2 promoter SNP309 is associated with risk of occurrence and advanced lymph node metastasis of nasopharyngeal carcinoma in Chinese population Clin Cancer Res 2007, 13(9):2627-2633. 10.1158/1078-0432.CCR-06-2281 17473193
40. Walsh CS Miller CW Karlan BY Koeffler HP Association between a functional single nucleotide polymorphism in the MDM2 gene and sporadic endometrial cancer risk Gynecol Oncol 2007, 104(3):660-664. 10.1016/ j.ygyno.2006.10.008 17123590
41. Menin C Scaini MC De Salvo GL Biscuola M Quaggio M Esposito G Belluco C Montagna M Agata S D'Andrea E Association between MDM2-SNP309 and age at colorectal cancer diagnosis according to p53 mutation status J Natl Cancer Inst 2006, 98(4):285-288. 16478747
42. Hu Z Ma H Lu D Qian J Zhou J Chen Y Xu L Wang X Wei Q Shen H Genetic variants in the MDM2 promoter and lung cancer risk in a Chinese population Int J Cancer 2006, 118(5):1275-1278. 10.1002/ijc.21463 16152608
43. Lind H Zienolddiny S Ekstrom PO Skaug V Haugen A Association of a functional polymorphism in the promoter of the MDM2 gene with risk of nonsmall cell lung cancer Int J Cancer 2006, 119(3):718-721. 10.1002/ ijc.21872 16496380
44. Rayburn E Zhang R He J Wang H MDM2 and human malignancies: Expression, clinical pathology, prognostic markers, and implications for chemotherapy Curr Cancer Drug Targets 2005, 5(1):27-41. 10.2174/ 1568009053332636 15720187
45. Zhang L Hill RP Hypoxia enhances metastatic efficiency by up-regulating Mdm2 in KHT cells and increasing resistance to apoptosis Cancer Res 2004, 64(12):4180-4189. 10.1158/0008-5472.CAN-03-3038 15205329
46. Ries S Biederer C Woods D Shifman O Shirasawa S Sasazuki T McMahon M Oren M McCormick F Opposing effects of Ras on p53: Transcriptional activation of mdm2 and induction of p19ARF Cell 2000, 103(2):321-330. 10.1016/S0092-8674(00)00123-9 11057904
47. Shaulian E Resnitzky D Shifman O Blandino G Amsterdam A Yayon A Oren M Induction of Mdm2 and enhancement of cell survival by bFGF Oncogene 1997, 15(22):2717-2725. 10.1038/sj.onc.1201453 9400998
48. Slack A Chen Z Tonelli R Pule M Hunt L Pession A Shohet JM The p53 regulatory gene MDM2 is a direct transcriptional target of MYCN in neuroblastoma Proc Natl Acad Sci USA 2005, 102(3):731-736. 545522 15644444 10.1073/pnas.0405495102
49. Lynch CJ Milner J Loss of one p53 allele results in four-fold reduction of p53 mRNA and protein: A basis for p53 haplo-insufficiency Oncogene 2006, 25(24):3463-3470. 10.1038/sj.onc.1209387 16449974
50. Hong Y Miao X Zhang X Ding F Luo A Guo Y Tan W Liu Z Lin D The role of P53 and MDM2 polymorphisms in the risk of esophageal squamous cell carcinoma Cancer Res 2005, 65(20):9582-9587. 10.1158/ 0008-5472.CAN-05-1460 16230424
51. Allazzouzi H Suriano G Guerra A Plaja A Espin E Armengol M Alhopuro P Velho S Shinomura Y Gonzalez-Aguilera JJ Tumour selection advantage of non-dominant negative p53 mutations in homozygous mdm2-snp309 colorectal cancer cells J Med Genet 2007, 44(1):75-80. 10.1136/jmg.2006.042572 16825434
52. Sanchez-Carbayo M Socci ND Kirchoff T Erill N Offit K Bochner BH Cordon-Cardo C A polymorphism in HDM2 (SNP309) associates with early onset in superficial tumors, TP53 mutations, and poor outcome in invasive bladder cancer Clin Cancer Res 2007, 13(11):3215-3220. 10.1158/ 1078-0432.CCR-07-0013 17545525
53. Tsuiki H Nishi T Takeshima H Yano S Nakamura H Makino K Kuratsu J Single nucleotide polymorphism 309 affects murin-double-minute 2 protein expression but not glioma tumorigenesis Neurol Med Chir (Tokyo) 2007, 47(5):203-208. discussion 208-209. 10.2176/nmc.47.203 17527046
54. Allazzouzi H Suriano G Guerra A Plaja A Espin E Armengol M Alhopuro P Velho S Shinomura Y Gonzalez-Aguilera JJ Tumour selection advantage of non-dominant negative p53 mutations in homozygous mdm2-snp309 colorectal cancer cells J Med Genet 2007, 44(1):75-80. 10.1136/jmg.2006.042572 16825434